Bimatoprost
As of the edition of 20 October 2026, Bimatoprost is a small molecule: marketed, first approved in 2001 (US); acts on PTGFR; US protection ends in 2031.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Lumigan
- First approved
- 16 March 2001 (US)
- Approvals on record
- 20 in 8 regions
- Holder of the most recent approval
- Thea Pharma; 7 holders in all
- Registered trials
- 108, 6 stopped early
- Disease areas
- Eye; Skin and connective tissue; Immune system; Inherited and neonatal; Hormones; Cancer
US protection
US protection ends in 2031.
The last listed US drug-substance patent ends in 2031. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Bimatoprost.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGFR | Prostaglandin F2-alpha receptor | P43088 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 20 | 16 | 1 | 1 |
| Phase 1 | 8 | 5 | 1 | 1 |
| Phase 2 | 19 | 16 | 1 | 0 |
| Phase 3 | 28 | 25 | 1 | 2 |
| Phase 4 | 33 | 27 | 1 | 2 |
| All trials | 108 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Originator, Applicant and Lead sponsor of trials | 2001 to now |
| Senju Pharmaceutical | Applicant | 2009 to now |
| Thea Pharma | Applicant | 2023 to now |